Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 18, 2025
Transactions
24
Purchases
7
Sales
17
Purchase value
$214.87K
Sale value
$5.47M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Sep 14, 2026Period of report Sep 14, 20260002070664-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 14, 2026
Common StockF2
10,175
$18.4478
$187.71K
380,824
Direct
Filing footnotes · 3
F1Includes 1,748 shares of Common Stock acquired on June 30, 2026 pursuant to the Issuer's 2025 Employee Stock Purchase Plan.
F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.22 to $18.63, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein. The shares of Common Stock were sold solely to cover the exercise price in connection with the exercise of the stock option.
F3The stock option is fully vested and currently exercisable.
Filed Aug 28, 2026Period of report Aug 26, 20260001193125-26-374359
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 26, 2026
Common StockF1
1,196
$22.60
$27.03K
2,185,914
IndirectSee footnote
Filing footnotes · 1
F1Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
Filed Aug 24, 2026Period of report Aug 20, 20260001193125-26-363913
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 24, 2026
Common StockF3F1
681
$22.62
$15.40K
2,187,110
IndirectSee footnote
SaleAug 21, 2026
Common StockF2F1
20,516
$22.61
$463.87K
2,187,791
IndirectSee footnote
SaleAug 20, 2026
Common StockF1
3,900
$22.60
$88.14K
2,208,307
IndirectSee footnote
Filing footnotes · 3
F1Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
F2This figure is the weighted average sales price of multiple trades ranging from $22.60 to $22.67 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $22.78 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Matthew Fraser AhearnDirector · Chief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Aug 18, 2026Period of report Aug 14, 20260002070582-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 18, 2026
Common StockF1F3
12,586
$20.9354
$263.49K
245,776
Direct
SaleAug 18, 2026
Common StockF1F4
1,600
$21.3819
$34.21K
244,176
Direct
SaleAug 17, 2026
Common StockF1F2
8,314
$20.0988
$167.10K
258,362
Direct
Filing footnotes · 4
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $20.00 to $20.525, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
F3The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $20.25 to $21.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
F4The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $21.25 to $21.46, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
Filed Aug 7, 2026Period of report Aug 5, 20260001193125-26-340260
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 6, 2026
Common StockF2
2,095
$22.60
$47.35K
2,212,207
IndirectSee footnote
SaleAug 5, 2026
Common StockF1F2
7,338
$22.64
$166.13K
2,214,302
IndirectSee footnote
Filing footnotes · 2
F1This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.00 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335278
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 4, 2026
Common StockF3F2
99,812
$22.77
$2.27M
2,221,640
IndirectSee footnote
SaleAug 3, 2026
Common StockF1F2
10,751
$22.71
$244.16K
2,321,452
IndirectSee footnote
Filing footnotes · 3
F1This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.05 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.04 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Filed Aug 3, 2026Period of report Jul 30, 20260001193125-26-330846
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 31, 2026
Common StockF3F2
20,034
$22.73
$455.37K
2,332,203
IndirectSee Footnote
SaleJul 30, 2026
Common StockF1F2
28,245
$23.36
$659.80K
2,352,237
IndirectSee Footnote
Filing footnotes · 3
F1This figure is the weighted average sales price of multiple trades ranging from $23.00 to $23.73 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
F2Held directly by Cooperatieve Gilde Healthcare V U.A. ("Gilde"). Gilde Healthcare V Management B.V. is the managing director of Gilde and has sole voting and dispositive power with respect to the shares held by Gilde. Gilde Healthcare V Management B.V. is owned by Gilde Healthcare Holding B.V. The managing partners of Gilde Healthcare Holding B.V. are Manapouri B.V. (of which Edwin de Graaf is the owner and managing director) and Martemanshurk B.V. (of which Pieter van der Meer is the owner and managing director). Geoff Pardo is a partner at Gilde and may be deemed to share voting and dispositive power with respect to the shares held of record by Gilde. Mr. Pardo disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
F3This figure is the weighted average sales price of multiple trades ranging from $22.60 to $23.00 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, Shoulder Innovations, Inc. or any security holder of Shoulder Innovations, Inc. full information about the number of shares sold at each separate price upon request.
Matthew Fraser AhearnDirector · Chief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 12, 20260002070582-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 15, 2026
Common StockF1F4
1,644
$18.2005
$29.92K
271,676
Direct
SaleJun 15, 2026
Common StockF1F5
2,500
$19.2592
$48.15K
269,176
Direct
SaleJun 12, 2026
Common StockF1F2F3
15,856
$18.6797
$296.19K
273,320
Direct
Filing footnotes · 5
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.29 to $19.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
F3Includes the following shares received without consideration as an in-kind distribution: 2,411 shares from Genesis Investment Holdings. In prior reports, the reporting person reported beneficial ownership of 286,765 shares of Shoulder Innovations common stock held directly.
F4The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $17.98 to $18.88, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
F5The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.98 to $19.71, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein.
Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Mar 17, 2026Period of report Mar 13, 20260002070664-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseMar 13, 2026
Common StockF1
2,200
$15.1782
$33.39K
278,866
Direct
Filing footnotes · 1
F1The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.80 to $15.50, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
Robert Joseph BallDirector · CEO & Executive Chairman
4
Filed Dec 15, 2025Period of report Dec 11, 20250001628280-25-057067
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseDec 12, 2025
Common StockF2
3,900
$14.8911
$58.08K
118,457
Direct
PurchaseDec 11, 2025
Common StockF1
3,300
$14.8285
$48.93K
114,557
Direct
Filing footnotes · 2
F1The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.56 to $15.16, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
F2The price reported in Column 4 is a weighted average purchase price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $14.60 to $15.26, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth herein.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.